Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859124 | 0.83 | SIGMAR1 (0.45) | SIGMAR1 | |
| SCHEMBL8918158 | 0.79 | CA1 (0.49) | CA1CA2CA4CA9 | |
| SCHEMBL6174357 | 0.78 | ALDH1A1 (0.51) | — | |
| Acetamide SCHEMBL7303967 | 0.78 | CA1 (0.50) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL6244506 | 0.78 | MC4R (0.49) | SIGMAR1CA1CA2CA4CA9 | |
| SCHEMBL24326317 | 0.77 | SIGMAR1 (0.67) | SIGMAR1 | |
| SCHEMBL3436828 | 0.77 | SIGMAR1 (0.67) | SIGMAR1 | |
| SCHEMBL2538770 | 0.76 | CA1 (0.62) | CA1CA2CA4CA9 | |
| SCHEMBL29455824 | 0.75 | LTA4H (0.47) | SIGMAR1 | |
| SCHEMBL29317145 | 0.75 | DPP4 (0.42) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | SIGMAR1 4090/4885CA1 3679/4885CA2 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.